Tag: lutetium Lu 177 vipivotide tetraxetan

Home / lutetium Lu 177 vipivotide tetraxetan

Categories

Pluvicto is approved by FDA for metastatic castration-resistant prostate cancer

April 2022: The Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., a Novartis company) for the treatment of adult patie...
lutetium-lu-177-vipivotide-tetraxetan

Scan the code